Knowledge, attitude and practice of community pharmacist towards COVID-19 and uses of zinc and doxycycline in COVID-19

N. Venkatesh; E. Bhavya; K. Vivekanandan

doi:10.53730/ijhs.v6nS3.7310

Authors

Venkatesh N. School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India
E. Bhavya
bhavya.sps@velsuniv.ac.in
Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India
Vivekanandan K. Department of Pharmacy Practice, Faculty of Pharmacy, Dr.M.G.R. Educational and Research Institute, Deemed to be University, Maduravoyal, Chennai-6000095

Keywords:

knowledge, attitude, community pharmacist, COVID-19, zinc, doxycycline

Abstract

The public must routinely practice precautionary behaviors to control the spread of COVID-19, as no vaccines and antiviral treatments are currently available. This paper examines the public’s Knowledge, Attitudes, and Practices (KAP) related to COVID-19 and their relationships and identified the pandemic’s vulnerable populations to provide recommendations for behavioral interventions and policies. To Determine the Knowledge, Attitude and Practice of Community Pharmacists towards COVID- 19 and use of Zinc and Doxycycline in COVID-19 and the objective is to understand the knowledge of community pharmacist regarding use of zinc and Doxycycline in COVID-19. This is the cross sectional study conducted among the Community Pharmacists in and around Avadi, Chennai. This study assess the knowledge attitude and perception of community pharmacist regarding Zinc and Doxycycline use in COVID- 19, In comparison of individual KAP of community pharmacist with their work experience there was no significant difference with respect to their work experience all showed a good knowledge, positive attitude and positive perception regarding the use of Zinc and Doxycycline in COVID- 19, the value are 0.3 for knowledge, 0.5 for attitude and 0.3 for perception.

Downloads

Download data is not yet available.

References

Narendrakumar L, Joseph I, Thomas S. Potential Effectiveness and Adverse Implications of Repurposing Doxycycline in COVID-19 Treatment. Expert Review of Anti-infective Therapy. 2021 Aug 3.

Vivekanandan.K, N. Venkatesh, E. Bhavya. Role of Doxycycline in COVID- 19- A review. Annals of R.S.C.B.2021, 25(3), 3686-88.

Ali AS, ASattar MA, Karim S, Kutbi D, Aljohani H, Bakhshwin D, Alsieni M, Alkreathy HM. Pharmacological basis for the potential role of Azithromycin and Doxycycline in management of COVID-19. Arabian Journal of Chemistry. 2021 Mar;14(3):102983.

Holmes NE, Charles PG. Safety and efficacy review of doxycycline. Clinical Medicine. Therapeutics. 2009 Jan;1:CMT-S2035.

Saber-Ayad M, Saleh MA, Abu-Gharbieh E. The rationale for potential pharmacotherapy of COVID-19. Pharmaceuticals. 2020 May;13(5):96.

Sodhi M, Etminan M. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2020 May;40(5):487-8.

Bartoli A, Gabrielli F, Alicandro T, Nascimbeni F, Andreone P. COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. Internal and Emergency Medicine. 2021 Jan 4:1-28.

Malek AE, Granwehr B, Kontoyiannis DP. Doxycycline as a potential partner of COVID-19 therapies.

Saber-Ayad M, Saleh MA, Abu-Gharbieh E. The rationale for potential pharmacotherapy of COVID-19. Pharmaceuticals. 2020 May;13(5):96.

Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, Wurtz N, Rolain JM, Colson P, La Scola B, Raoult D. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microbial pathogenesis. 2020 Aug 1;145:104228.

Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging (Albany NY). 2020 Apr 30;12(8):6511.

Alam MM, Mahmud S, Rahman MM, Simpson J, Aggarwal S, Ahmed Z. Clinical outcomes of early treatment with doxycycline for 89 high-risk COVID-19 patients in long-term care facilities in New York. Cureus. 2020 Aug;12(8).

Yates PA, Newman SA, Oshry LJ, Glassman RH, Leone AM, Reichel E. Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease. Therapeutic advances in respiratory disease. 2020 Sep;14:1753466620951053.

Ahmad I, Alam M, Saadi R, Mahmud S, Saadi E. Doxycycline and hydroxychloroquine as treatment for high-risk COVID-19 patients: Experience from case series of 54 patients in long-term care facilities. MedRxiv. 2020 Jan 1.

Conforti C, Giuffrida R, Zalaudek I, Di Meo N. Doxycycline, a widely used antibiotic in dermatology with a possible anti‐inflammatory action against IL‐6 in COVID-19 outbreak. Dermatologic therapy. 2020 Apr 20.

Di Caprio R, Lembo S, Di Costanzo L, Balato A, Monfrecola G. Anti-inflammatory properties of low and high doxycycline doses: an in vitro study. Mediators of inflammation. 2015 Oct; 2015.